Remove Clinical Trials Remove Insulin Remove Vaccination Remove Vaccine
article thumbnail

Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?

XTalks

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes.

article thumbnail

Looking back at 2022: The top healthcare stories

Pharmaceutical Technology

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. A few months later, the monkeypox outbreak showed the difficulty in accessing vaccines and antivirals despite a plan to stockpile them. Tracking the news.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diamyd Diabetes Vaccine Study gets Green Light to Resume by the FDA

XTalks

In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. XTALKS WEBINAR: The Clinical Trial Diversity Puzzle: How can the Industry do Better? Live and On-Demand: Thursday, January 26, 2023, at 1pm EST (10am PST).

article thumbnail

Magazine: ‘Right shoring’ API production in Europe

Pharmaceutical Technology

More than a century after an individual with type 1 diabetes was treated with insulin for the first time, the FDA approved Tzield, the first and only treatment to delay the onset of type 1 diabetes. Also in this month’s issue, we take a look at the innovative type 1 diabetes therapy by Provention Bio called Tzield.

article thumbnail

FDA Approves First Drug to Delay T1D + Positive Data for Pfizer’s Maternal RSV Vaccine – Xtalks Life Science Podcast Ep. 87

XTalks

Ayesha also talked about the latest positive Phase III trial data that Pfizer recently shared for its maternal RSV vaccine candidate. Hear more about the vaccine trial data, based on which an independent data monitoring committee has recommended that Pfizer file with the FDA for approval.

article thumbnail

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

Delveinsight

AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy. The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate.

article thumbnail

Eli Lilly’s Type 2 Diabetes Shot Tirzepatide Emerges Winner Against Semaglutide

XTalks

Related: Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula? GLP-1 receptor agonists lower blood glucose levels by increasing the production of insulin. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. cells in the pancreas.

Insulin 97